TickerHumSide-by-side comparison
AbbVie vs Gilead Sciences
As of Nov 11, 2026, P/S is 7.8x for AbbVie vs 6.8x for Gilead Sciences; revenue growth is 10.7% for AbbVie vs 6.5% for Gilead Sciences; operating margin is 32.2% for AbbVie vs -7.6% for Gilead Sciences; net margin is 15.7% for AbbVie vs -12.5% for Gilead Sciences.
What stands out
- AbbVie keeps more of each sale as operating profit: 32.2% margin vs -7.6% for Gilead Sciences.
- AbbVie scores higher on TickerHum's ratings: 62/100 vs 45/100 for Gilead Sciences.
Key metrics
| Metric | ABBV | GILD |
|---|---|---|
| Price | $292.77 | $169.77 |
| Market cap | $517.5B | $210.57B |
| P/E | 50.4x (#1) | — |
| P/S | 7.8x (#2) | 6.8x (#1) |
| Revenue growth | 10.7% (#1) | 6.5% (#2) |
| Operating margin | 32.2% (#1) | -7.6% (#2) |
| Net margin | 15.7% (#1) | -12.5% (#2) |
| Debt / equity | — | 1.83 (#1) |
| 1-year return | +25.5% (#2) | +37.6% (#1) |
| Research score | 62/100 (#1) | 45/100 (#2) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- AbbVie Inc. (ABBV) — Drug Manufacturers—General
- Gilead Sciences, Inc. (GILD) — Drug Manufacturers—General